Investor Relations

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area of oncology with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has promising product candidates in clinical and late preclinical development and has entered into strategic collaborations with leading global pharmaceutical companies.

Recent News > MORE
Date Title  
Wednesday, January 4, 2017 Five Prime Therapeutics and Bristol-Myers Squibb Extend Research Term in Collaboration to Discover Novel Immuno-Oncology Therapies for Three Immune Checkpoint Pathways
Tuesday, January 3, 2017 Five Prime Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
Upcoming and Recent Events > MORE
Date Title  
Tuesday, January 10, 2017
9:30 AM PT
35th Annual J.P. Morgan Healthcare Conference
Supporting Materials
PDF View Presentation  5.3 MB   Add to Briefcase
Thursday, December 8, 2016
8:00 AM ET
Five Prime Therapeutics Research & Development Day
Location New York City, NY
Supporting Materials
PDF View Presentation  22.1 MB   Add to Briefcase
Monday, November 7, 2016
2:00 PM MT
Credit Suisse 25th Annual Healthcare Conference
Location The Phoenician
Scottsdale , AZ
Supporting Materials
PDF Corporate Overview   2.1 MB   Add to Briefcase

FPRX (Common Stock)

Exchange
NASDAQ
Price
43.50
Change (%)
-2.58
Volume
459,545

Data as of 4:00 PM ET on Friday, January 20, 2017
Minimum 20 minute delay
Refresh quote
Powered By eSignal, Inc.